All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Allogeneic I-CreI Enzyme Gene Editing chimeric antigen receptor (CAR)-T cell therapy is a cutting-edge approach to cancer treatment that combines the power of CAR-T cell therapy with gene editing technology using the I-CreI enzyme. Creative Biolabs has developed an I-CreI enzyme-based gene editing service for CAR-T cells to precisely edit the DNA of these cells to improve their targeting ability and enhance their effectiveness in destroying cancer cells.
I-CreI is a type of genome-editing enzyme that is derived from a homing endonuclease. This enzyme is known for its high specificity and efficiency in creating site-specific double-strand breaks in DNA. It is often used in genetic engineering applications to precisely modify the genome of a variety of organisms. I-CreI recognizes and cleaves a specific DNA sequence, making it a highly valuable tool for targeted gene editing. By harnessing the power of I-CreI to edit the genes of a wide range of organisms, from bacteria to plants to animals, it has the potential to revolutionize the field of molecular biology.
Creative Biolabs edits T cells with the I-CreI enzyme to remove specific genes that may interfere with their ability to effectively target and kill cancer cells. The edited T cells are then engineered to express a CAR that targets a specific antigen in cancer cells, allowing them to recognize and attack the cancer cells more effectively.
Creative Biolabs offers gene editing technologies, such as CRISPR-Cas9, to target and modify specific genes in cells. In the context of CAR T cell therapy, I-CreI enzymes can be used to improve the efficacy of CAR T cells by precisely modifying specific genes associated with the function and activation of these cells:
I-CreI enzyme can be used to disrupt genes that encode for inhibitory proteins, such as PD-1, that may prevent the activity of CAR T cells. By inactivating these genes, the CAR T cells may be able to better recognize and attack cancer cells.
I-CreI enzyme can also be used to insert genes that enhance the function of CAR T cells, such as genes encoding for cytokines or costimulatory molecules. This can help improve the persistence and potency of CAR T cells in attacking cancer cells.
Precise editing of the CAR-T cell's targeting mechanism, enhancing the cell's ability to specifically target cancer cells while minimizing off-target effects.
Improve the cell's overall efficacy in killing cancer cells, leading to better treatment outcomes.
Reduce the risk of toxicity and side effects associated with CAR-T cell therapy, improving the overall safety profile of the treatment.
Improve the persistence of CAR-T cells in the body, allowing for longer-lasting treatment effects and potentially reducing the likelihood of cancer relapse.
Create off-the-shelf CAR-T cell therapies that can be more readily available to a wider range, regardless of HLA matching.
We are proud to be your trusted allogeneic I-CreI enzyme gene editing CAR-T cell service provider. Our team of dedicated experts ensures that each patient receives personalized and effective treatment tailored to their specific needs. We value the trust and cooperation of our clients and work tirelessly to deliver the highest quality care possible. By working together, we can achieve the best possible outcomes for you and continue to advance the field of gene editing therapy. Thank you for trusting us with your care.
Our I-CreI Enzyme Gene Editing Cell Development Service offers cutting-edge technology to generate precise genetic modifications in a variety of cell types. With our expertise and state-of-the-art facilities, we can assist you in efficiently editing your cells to meet your research and therapeutic needs.
If you are interested in learning more about how our service can benefit your projects or have any questions regarding our capabilities, please do not hesitate to contact us. We are committed to providing high-quality support and helping you achieve your scientific goals through expert gene editing services. Don't delay, reach out to us today to discuss your cell development needs!
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION